Nanoform Finland Oyj · OMXHEX:NANOFH
Nanoform Finland Oyj — PODD 2022 (Partnerships and Opportunities in Drug Delivery)
28 slides from Nanoform Finland Oyj's conference presentation, Oct 25, 2022
Slide 1: How drug delivery is enabling a clinical trial for Glioblastoma
How drug delivery is enabling a clinical trial for Glioblastoma With Christian Jones, CCO at Nanoform & João Seixas, PhD, CEO at TargTex Featured partnership talk at PODD 2022 October 25th, 2022, 10am EDT
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform’s and its partners strategy, business plans, technology, and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “antici
Slide 3: Executive Summary
Executive Summary TargTex and Nanoform Present Tumour Eradication in Rodents from a Nanoformed Glioblastoma drug TargTex CEO Dr João Seixas and Nanoform CCO Christian Jones presented on October 25th highly promising in-vivo data, enabled by a nanoformed drug product for the treatment of glioblastoma
Slide 4: Introduction to Nanoform
= = je) ue ie) Cc ©O = fe} ow) Cc ie) p O =) ao) ie) Lu WY Cc eS
Slide 5: Nanoform in a snapshot
Nanoform in a snapshot The Share Nanoform Platform Technology • Listed June 4th, 2020, on • Global experts in nanotechnology Bulk and • CESS® technology for small drug particle engineering molecules (chemical Nasdaq First North Premier Growth Market in Helsinki API compounds) discovered in and Stock
Slide 6: Unveiling of the new patient statue
We were delighted to gather the entire Nanoform team for the unveiling of our new patient statue. Embodying our dedication to improving patient lives, it has taken pride of place in our Helsinki headquarters, and it will continue to inspire the Nanoform team to expand the possibilities for patients
Slide 7: Our nanoforming technologies
Our nanoforming technologies 7
Slide 8: Patented technology nanoforming API particles
Patented technology nanoforming API particles The Controlled Expansion of Supercritical Solutions - CESS® Possibility to recycle CO2 > Supercritical CO2 is guided into a pressure 1 vessel loaded with API 1 4 2 > Increasing the pressure and temperature in the 2 vessel dissolves the API in supercritic
Slide 9: Small is a platform enabler across drug delivery
Small is a platform enabler across drug delivery Enhanced drug loading and release in hydrogel formulation for brain Rapid absorption of poorly delivery (Glioblastoma) NPI-001 and NPI-002 enhanced soluble Piroxicam ocular tissue penetration UK Respiratory Biotech Localized lung delivery Co-Polymer N
Slide 10: Glioblastoma: history and progress
Glioblastoma: history and progress 10
Slide 11: History
History Target: Calcium Channel Associated with Angiogenesis Extracellular Lateral View Intracellular Machine Learning Algorithm Infers a SM-Target Link Glioblastoma (GBM) Small Molecule (SM) with Anticancer Properties Reported 11
Slide 12: Glioblastoma (GBM)
Glioblastoma (GBM) Most common and aggressive primary brain tumor 16 months life expectancy 1 FDA approved drug in the last 20 years ±200k yearly \CHEMOTHERAPY TOXIC DRUG Recurrence STOP After ± 9m RADIOTHERAPY Blood- Brain Craniotomy Barrier 12
Slide 13: Developing a solution
Developing a solution 13
Slide 14: Drug response in primary patient samples
Drug Drug response in primary patient samples Does not affect healthy cell population in tumor microenvironment like SoC Responds to SoC resistant tumors Equipotent against GBM stem-like cells 14
Slide 15: Avoid Recurrence
Solution Local implantation of selective Ca2+ channel blocker Avoid in a hydrogel as adjunct to surgery Recurrence Craniotomy Inject GBM TUMOUR cells In vivo Drug-doped model Hydrogel 15
Slide 16: Validation of localized therapy approach with first prototype hydrogel
Validation of localized therapy approach with first prototype hydrogel Single dose administration of the drug@hydrogel formulation abolishes Primary GBM with safe histological profile 16
Slide 17: Development
Development Repuction Particre Size “Nanororminc” Brain Surcery “Tumour PP a a i Tusion/Erricacy Desuikinc” Apsunct \Y . -To- . Surcery
Slide 18: Development of tailored hydrogel
Development of tailored hydrogel Drug Delivery Challenge The first prototype hydrogel was effective for primary tumor eradication but did not stop tumor recurrence. This formulation also had limited dosing possibility. Hydrogel Optimization • Thermo-responsive hydrogel • Sterilizable, non-toxic, bio
Slide 19: Development of tailored formulation
Development of tailored formulation Hydrogel Optimization Excipients Screening Nanomilling Nanoformed material Solubility Tuning of release kinetics Particle size control % API incorporation Need for stabilizers and/or additives Storage stability GMP-scale up 19
Slide 20: Results
Results 20
Slide 21: Development – Results: Nanoformed hydrogel diffusion
Development – Results: Nanoformed hydrogel diffusion Nanoformed particles enable deep drug diffusion across the brain parenchyma. 24h post-dosing 72h post-dosing Untreated rat brain Drug penetration through rat brain parenchyma (green & yellow) Drug penetration through rat brain parenchyma (green) 2
Slide 22: Efficacy – Complete Tumor Eradication with Nanoformed hydrogel
Efficacy – Complete Tumor Eradication with Nanoformed hydrogel RNU-U87 xenograft rat model Untreated Treated 40% Long Term Survivals with Day 12 post treatment complete tumor eradication Hydrogel Tumor Tumor Untreated Treated group Next Steps: increase drug load and T tumor br brain improve % surviv
Slide 23: Looking to the future
Looking to the future 49 nanoform nanoform.com smallis powerful® @nanoformf 23
Slide 24: Roadmap
Roadmap Phase 1/2a clinical trial Dose-escalation study to assess safety, tolerability and preliminary efficacy. Meeting with Multicentre global trial FDA and EMA (pre-IND and Efficacy Endpoints Scientific Progression Free Survival and Advise Overall Survival (OS) 2022 meetings) 2024 2029 2030 2023
Slide 25: Product Differentiation for GBM
Product Differentiation for GBM One-time and efficient treatment Easy preparation and application during surgery Large addressable patient pool 1 Its mechanism of action involves a target that is widely expressed in the GBM population Local delivery It does not have to cross the BBB, which is one of
Slide 26: Summary
Summary 26
Slide 27: TargTex and Nanoform Partnership Enabled….
TargTex and Nanoform Partnership Enabled…. • Tumor eradication in rodents (rat) with only 44% of maximum drug loading dose • Deep brain penetration demonstrated by MSI (Mass Spectrometry Imaging) • PK data shows no systemic exposure • Non-toxic at maximum loading concentration • GMP-scalable formula
Slide 28: Further Enquiries
FURTHER ENQUIRIES CFO Albert Hæggström albert.haeggstrom@nanoform.com +358 29 370 0150 CCO Christian Jones christian.jones@nanoform.com +44 7804 474 771 Director of Investor Relations Henri von Haartman hvh@nanoform.com +46 7686 650 11
Nanoform Finland — PODD 2022 (Partnerships and Opportunities in Drug Delivery) on 6ix